Dong MA | Cardiovascular Researches | Best Researcher Award

Posted on by Pencis

Prof. Dong MA | Cardiovascular Researches | Best Researcher Award

Prof. Dong MA, Hebei Medical University, China

Prof. Dong Ma is a distinguished professor at Hebei Medical University, China, specializing in medical sciences and healthcare innovations. With a strong academic background, he has made significant contributions to biomedical research, clinical studies, and medical advancements. His work focuses on developing new treatments, improving patient care, and enhancing healthcare methodologies. Prof. Ma’s research is widely cited in prestigious medical journals, influencing global healthcare policies and practices. As a mentor and scholar, he continues to inspire future medical professionals while fostering international research collaborations. His dedication to medical excellence and innovation ensures a lasting impact in the field.

AUTHOR PROFILE

Scopus Profile

🎓 EARLY ACADEMIC PURSUITS:

Prof. Dong Ma embarked on his academic journey with a strong foundation in medical sciences. He pursued his education in China, demonstrating exceptional aptitude in the field of medicine and research. His early academic years were marked by rigorous studies, participation in innovative projects, and a keen interest in medical advancements.

🏛️ PROFESSIONAL ENDEAVORS:

Prof. Ma is currently a distinguished professor at Hebei Medical University, China. Throughout his career, he has been actively involved in teaching, mentoring, and guiding students in medical sciences. His professional engagements extend beyond the classroom, contributing to the university’s research and global collaborations in medical research and healthcare advancements.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIOVASCULAR RESEARCHES:

Prof. Ma’s research primarily revolves around medical sciences, healthcare innovations, and clinical applications. His work includes:

  • Biomedical Research: Investigating novel treatments and technologies in the medical field.
  • Clinical Studies: Conducting evidence-based research to improve patient care and treatment outcomes.
  • Medical Innovations: Developing and contributing to new methodologies and technologies in healthcare.

His dedication to research has significantly impacted both theoretical knowledge and practical medical applications, benefiting healthcare professionals and patients alike.

🌍 IMPACT AND INFLUENCE:

Prof. Ma’s contributions have made a profound impact on the medical community. His research has been cited extensively in academic journals, influencing policies and practices in the field of medicine. His work has also led to collaborations with international medical institutions, further amplifying his influence on global healthcare development.

📖 ACADEMIC CITATIONS:

Prof. Ma has been cited in numerous prestigious medical journals and research papers. His publications cover a wide range of topics, including:

  • Advances in medical treatments and techniques.
  • Healthcare policy improvements.
  • Breakthroughs in disease prevention and management.

His academic work serves as a valuable resource for researchers, scholars, and healthcare professionals worldwide.

🏅 LEGACY AND FUTURE CONTRIBUTIONS:

Prof. Dong Ma’s legacy is built upon his relentless pursuit of medical excellence. His future contributions are expected to:

  • Drive Innovation: Further enhance medical technologies and treatment approaches.
  • Inspire Future Scholars: Mentor upcoming medical professionals and researchers.
  • Expand Global Collaborations: Strengthen research ties with international institutions for broader healthcare advancements.

🔥 CONCLUSION:

Prof. Dong Ma stands as a visionary leader in medical sciences, shaping the future of healthcare through groundbreaking research, innovation, and education. His dedication to improving patient care, advancing medical treatments, and mentoring future professionals has left a lasting impact on both academia and clinical practice. With numerous contributions to medical research and extensive collaborations worldwide, he continues to drive progress in healthcare. His legacy is defined by excellence, knowledge, and a passion for medical advancements, ensuring a brighter, healthier future for generations to come.

TOP NOTABLE PUBLICATIONS

The Impact of the Monocyte-to-High-Density Lipoprotein Cholesterol Ratio on the Prognosis of Patients with Non-Viral,Non-Alcoholic Hepatocellular Carcinoma:a Retrospective Cohort Study

Authors: Xianzhe Lou, Tongguo Miao, Shiya Zhang, Dong Ma, Yuemin Nan

Journal: Chinese General Practice

Year: 2025

Combined DeRitis ratio and alkaline phosphatase on the prediction of portal vein tumor thrombosis in patients with hepatocellular carcinoma

Authors: Tongguo Miao, Shiya Zhang, Yunjing Zhang, Dong Ma, Yuemin Nan

Journal: Scientific Reports

Year: 2024

Study on the relationship between Methylation of Neuregulin (NRG) Gene and Cervical Carcinoma

Authors: Xizhao Yan, Fenglan An, Zhenzhen Ding, Dong Ma, Xiaohui Yang

Journal: Pakistan Journal of Medical Sciences

Year: 2024

α-HBDH is a superior to LDH in predicting major adverse cardiovascular events in patients with acute aortic dissection

Authors: Yunjing Zhang, Yue Sun, Yongbo Zhao, Dong Ma

Journal: Heliyon

Year: 2024

Monocyte-to-High-Density Lipoprotein-Cholesterol Ratio Predicts Prognosis of Hepatocellular Carcinoma in Patients with Metabolic-Associated Fatty Liver Disease

Authors: Tongguo Miao, Xianzhe Lou, Shiming Dong, Dong Ma, Yuemin Nan

Journal: Journal of Hepatocellular Carcinoma

Year: 2024

Zhuofeng Lin | Myocardial infarction | Best Researcher Award

Posted on by Pencis

Prof. Dr. Zhuofeng Lin | Myocardial infarction | Best Researcher Award 

Prof. Dr. Zhuofeng Lin, Guangdong Medical University, China

Prof. Dr. Zhuofeng Lin is the Dean of the Experimental Animal Center and Dean of the Innovational Center of Cardiometabolic Disease at Guangdong Medical University, China. His research focuses on cross-organ communication in cardiovascular and metabolic diseases, particularly the role of metabolic hormones and obesity. He has made significant contributions to understanding FGF21 metabolic regulation, impacting blood glucose stability, blood pressure control, and anti-atherosclerosis therapies. His work also explores new targets for anti-myocardial infarction, heart failure, and vascular calcification drugs, driving innovation in metabolic and cardiovascular medicine. His research is widely recognized in international medical science.

AUTHOR PROFILE

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Dr. Zhuofeng Lin’s academic journey began with a strong foundation in medical sciences, focusing on cardiovascular and metabolic diseases. His early research explored physiological mechanisms and metabolic interactions, leading him to specialize in cross-organ communication and metabolic regulation. His education and initial training laid the groundwork for his extensive contributions to cardiometabolic research.

🏢PROFESSIONAL ENDEAVORS:

Prof. Lin has held prestigious positions at Guangdong Medical University, where he currently serves as:

  • Dean of the Experimental Animal Center 🐁
  • Dean of the Innovational Center of Cardiometabolic Disease 🫀

His leadership in these institutions has driven significant advancements in experimental research methodologies and the development of innovative treatment strategies for metabolic disorders.

🔍CONTRIBUTIONS AND RESEARCH FOCUS ON MYOCARDIAL INFARCTION:

Prof. Lin’s research is dedicated to practical applications, with a strong emphasis on:

  • Cross-organ communication in cardiovascular and metabolic diseases
  • Pathogenesis of cardiometabolic disorders linked to metabolic hormones and obesity
  • Fibroblast Growth Factor 21 (FGF21) and its role in metabolic regulation

His studies have provided groundbreaking insights into FGF21’s ability to regulate:
✅ Blood glucose levels
✅ Blood pressure stability
✅ Anti-atherosclerosis mechanisms
✅ Anti-Metabolic Dysfunction-Associated Steatohepatitis (MASH) therapies

Additionally, his work focuses on discovering new therapeutic targets for:
⚕️ Anti-myocardial infarction drugs
⚕️ Anti-heart failure treatments
⚕️ Anti-vascular calcification solutions

🌍IMPACT AND INFLUENCE:

Prof. Lin’s research has had a profound impact on global medical science, particularly in the fields of:
🔹 Metabolic disease management
🔹 Cardiovascular treatment innovations
🔹 Therapeutic drug development

His studies have influenced clinical practices, contributing to better patient outcomes in cardiovascular and metabolic health. His pioneering work in hormonal regulation and metabolic stability has inspired numerous scientists and researchers worldwide.

📄ACADEMIC CITES AND RECOGNITION:

Prof. Lin’s research is widely recognized in high-impact medical journals, with numerous citations supporting his theories. His work on FGF21 metabolic regulation is frequently referenced in the fields of endocrinology, cardiology, and metabolic research. He has been a keynote speaker at international medical conferences, sharing his insights with the global scientific community.

🚀LEGACY AND FUTURE CONTRIBUTIONS:

With an unwavering commitment to scientific innovation, Prof. Lin continues to shape the future of medical research. His ongoing projects aim to:
🔬 Develop novel cardiometabolic therapies
🔬 Enhance cross-organ communication research
🔬 Introduce cutting-edge treatments for heart disease and metabolic disorders

His legacy will be defined by his transformative contributions to medicine, paving the way for future breakthroughs in cardiovascular and metabolic health.

💡CONCLUSION:

Prof. Dr. Zhuofeng Lin is a pioneering leader in cardiometabolic research, making groundbreaking contributions to understanding metabolic regulation and cardiovascular health. His work on FGF21 has revolutionized approaches to blood glucose stability, blood pressure control, and anti-atherosclerosis treatments . With a vision for therapeutic innovation, he continues to explore new drug targets for heart failure, myocardial infarction, and vascular calcification . His impact on medical science is profound, shaping the future of metabolic and cardiovascular treatments. His dedication ensures lasting advancements in healthcare and patient well-being.

TOP NOTABLE PUBLICATIONS

Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice

Authors: Z Lin, H Tian, KSL Lam, S Lin, RCL Hoo, M Konishi, N Itoh, Y Wang, …
Journal: Cell Metabolism
Year: 2013

Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice

Authors: Z Lin, X Pan, F Wu, D Ye, Y Zhang, Y Wang, L Jin, Q Lian, Y Huang, …
Journal: Circulation
Year: 2015

Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile

Authors: Z Lin, Z Wu, X Yin, Y Liu, X Yan, S Lin, J Xiao, X Wang, W Feng, X Li
Journal: PLoS One
Year: 2010

Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues

Authors: L Geng, B Liao, L Jin, Z Huang, CR Triggle, H Ding, J Zhang, Y Huang, …
Journal: Cell Reports
Year: 2019

Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2

Authors: D Ye, K Yang, S Zang, Z Lin, HT Chau, Y Wang, J Zhang, J Shi, A Xu, …
Journal: Journal of Hepatology
Year: 2016

Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese

Authors: Z Lin, Z Zhou, Y Liu, Q Gong, X Yan, J Xiao, X Wang, S Lin, W Feng, X Li
Journal: PLoS One
Year: 2011

FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1–7) axis in mice

Authors: X Pan, Y Shao, F Wu, Y Wang, R Xiong, J Zheng, H Tian, B Wang, …
Journal: Cell Metabolism
Year: 2018

Adiponectin protects against acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice

Authors: Z Lin, F Wu, S Lin, X Pan, L Jin, T Lu, L Shi, Y Wang, A Xu, X Li
Journal: Journal of Hepatology
Year: 2014

Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling‐dependent manner

Authors: Y Pan, B Wang, J Zheng, R Xiong, Z Fan, Y Ye, S Zhang, Q Li, F Gong, …
Journal: Journal of Cellular and Molecular Medicine
Year: 2019

Dynamic change of serum FGF21 levels in response to glucose challenge in human

Authors: Z Lin, Q Gong, C Wu, J Yu, T Lu, X Pan, S Lin, X Li
Journal: The Journal of Clinical Endocrinology & Metabolism
Year: 2012